Globavir is an infectious disease-focused company with multiple drugs in development. Globavir’s development efforts will utilize a 505(b)(2) pathway for therapeutics which will have companion diagnostic tests on the drugs' labels. Globavir’s lead program in dengue will be in Phase II in 2015. Globavir’s proprietary platform can generate multiple drug candidates which will also utilize the same 505(b)(2) pathway.
Globavir’s patent protected diagnostic platform will be applicable for other infectious diseases such as: West Nile fever, Chickungunya, Yellow Fever, and Malaria. SNNLive spoke with Dr. Shalabh Gupta from Globavir at the Aegis Capital Corp. Healthcare & Technology Conference 2014 in Las Vegas, NV.
Dr. Gupta defines Globavir as a company focused on, “working on treatment of diseases for which there is no available treatment at the moment. We have put drugs as well as diagnostic platform and working on treatment of Dengue fever and Ebola.” He continues, “We found a way to combine existing drugs to use them in different indications other than they were approved for and all this technology was originally developed at Stanford.”
He explains that Ebola and Dengue have different names, “but they have one thing which is common, which is these are both hemorrhagic fevers and even though they belong to different genre in terms of the family of viruses, they have a homology. Our drugs work by blocking viruses’ entry into the cell and therefore these drugs work even if virus mutates.” He adds, “One of the challenges for many of these virus infections is that viruses that are smarter than the pharmaceutical companies, by the time companies figure out one way to treat a virus – virus mutated.” Dr. Gupta enlightens that Globavir’s drugs “work at the human cell level, it does not matter how quickly the virus is mutating, they are still able to work while other drugs do not work.” For more information, check out their website at globavir.com
© 2017 Stock News Now
Supported by Superior Web Solutions